Chinese vaccine enterprises shift from product export to capability transfer
China's human vaccine exports rose 53.51% year-on-year in 2025 to approximately $345 million, but the more consequential shift is structural: Chinese enterprises are now embedding manufacturing, regulatory, and R&D capabilities directly into partner countries rather than simply shipping product.
3 MIN READ · 25 SEP
Photo: Wikimedia CommonsPhoto: Prefeitura Campinas, Public domain / Wikimedia Commons
Subscriber Content
Subscribe to read the full analysis
Subscribe to read everything on GATE86
Already a subscriber? Log in
Follow this story
Useful?
Next in Today's signals
INDUSTRY · MOBILITY & EV
CATL and NIO pursue rival strategies to control China's battery-swapping market
4 MIN READ · 3 NOV
Related
ECONOMY · ASIA PACIFIC
Pinglu Canal surpasses 1 million tonnes in first month of operation
POLICY · EUROPE
EU adds €2 handling fee on small parcels from November 2026
INDUSTRY · MOBILITY & EV
